Clinical experience with regenerative therapy in heart failure

Abstract

Adoption of regenerative strategies for heart failure is challenged by mixed outcomes in clinical trials. Ongoing development plans strive to improve biotherapeutic potency, optimize delivery, standardize dosing, and target responsive patient populations. The CHART (Congestive Heart Failure Cardiopoietic Regenerative Therapy) program offers advanced experience in clinical development of next-generation regenerative therapies.